Suvorexant, marketed as Belsomra, is a medication primarily used for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance. It belongs to a class of drugs known as dual orexin receptor antagonists (DORAs). Unlike some traditional sleep medications that work by enhancing general brain inhibition, suvorexant targets a specific neurochemical system involved in wakefulness. It is available as an oral tablet and is classified as a Schedule IV controlled substance in the United States due to its potential for abuse, though this risk is considered low (FDA label, DrugBank).
The development of suvorexant represents a novel approach to managing insomnia, focusing on suppressing the wake-promoting signals rather than directly sedating the brain. This mechanism is designed to promote sleep more naturally by allowing the body's intrinsic sleep mechanisms to take over. It was approved by the U.S. Food and Drug Administration (FDA) in 2014. Patients considering suvorexant should have a thorough medical evaluation by a licensed clinician to determine its appropriateness for their specific condition.
Deep dive
Tap a section to expand.
Known interactions
Category rule: supplement × medication
Note
Some supplements change how the body processes medications (absorption, liver enzymes, or additive effects).
Specific pairs are checked against a licensed drug database and shown with their own severity. Always confirm with your provider or pharmacist.
Category rule: vitamin × medication
Note
Certain vitamins interact with specific medications (e.g., vitamin K with blood thinners).
Specific pairs are checked against a licensed source; confirm with your provider.
Compound-pair rule
Note
Additive sedation possible.
Start at low melatonin dose (0.3–1 mg) when combined with prescription sedatives.
Frequently asked
Sources referenced
* U.S. Food and Drug Administration (FDA) label for Belsomra
* DrugBank
* PubChem
* Mayo Clinic
* Examine.com
* Cochrane Library
Stackwise compiles summaries from publicly available scientific and regulatory references. Always verify important decisions with a licensed clinician.
Related compounds
Others in the medication category or studied for the same goals.
